The drug hydroxychloroquine, once touted by Donald Trump as a pandemic “game-changer,” should not be used to prevent Covid-19 and has no meaningful effect on patients already infected, a World Health Organization expert panel said.
Larger clinical trials are needed to assess whether Roche’s Actemra (tocilizumab) can cut death rates among the sickest Covid-19 patients after a small study found the arthritis drug was no better than standard care in severe cases.
Blocking TNF production could offer a more effective solution for the treatment of COVID-19.
Amgen, UCB and Takeda launched a global trial to identify whether any of three different drugs can reduce the severity of Covid-19 in hospitalized patients by moderating the immune system’s response to the disease.
Rockville, Maryland-based OncoImmune closed on a Series B round worth $56 million, co-led by HM Capital and a blue-chip investor.
Veru Inc. is developing a dual anti-inflammatory/antiviral medication to combat severe Covid-19 infections.
Gilead Sciences started an early-stage study of the company’s antiviral COVID-19 treatment remdesivir that can be inhaled, for use outside of hospitals.
British medical journal The Lancet has concerns about data behind an influential article that found hydroxychloroquine increased the risk of death in COVID-19 patients, a conclusion that undercut scientific interest in the medicine championed by U.S. President Donald Trump.
U.S. researchers, following the lead of scientists in other countries, launched studies to see whether widely available, low-cost generic drugs can be used to help treat the illness caused by the new coronavirus.
A clinical trial fell short of producing statistical evidence that Novartis’ anti-inflammatory drug Cosentyx can beat the world’s best-selling medicine Humira in treating a type of arthritis.